Would I FIE to You? FDA’s First Interchangeable Exclusivity Determination Results in Expiration
FDA Law Blog
JANUARY 11, 2024
Important to note here is that each interchangeable biosimilar was first approved as a biosimilar and each biosimilar manufacturer had been sued under the so-called “patent dance” procedure prior to seeking licensure of the biosimilar products as interchangeable.
Let's personalize your content